CooperCompanies is a medical-products and services company operating through CooperVision, which makes contact lenses, and CooperSurgical, which supplies fertility and women’s-health products and services. It sells in more than 130 countries and reports in U.S. dollars, with fiscal years ending October 31.
Loading the company summary…
A snapshot of what COOPER COMPANIES, INC. owns and owes at a point in time.
Read the company’s balance sheet in the original annual reports below.
Browse original filingsSee the original statement for its reporting period, currency, and unit.
3 reports in this collection
| Report period | Filed with SEC | Form | Source |
|---|---|---|---|
| Oct 31, 20230000711404-23-000072 | Dec 8, 2023 | 10-K | Open 10-Ksec.gov |
| Oct 31, 20240000711404-24-000074 | Dec 6, 2024 | 10-K | Open 10-Ksec.gov |
| Oct 31, 20250001628280-25-055615 | Dec 5, 2025 | 10-K | Open 10-Ksec.gov |
Dates describe the filing metadata. Figures and reporting periods should be checked against the original statement. SEC links open in a new tab.
Cooper’s contact-lens business remains its main operating-profit engine, but consolidated earnings require careful interpretation. Fiscal 2025 sales and operating cash flow increased while GAAP profit declined, principally as CooperSurgical absorbed write-offs, severance and acquired-intangible amortization. Subsequent fiscal 2026 results became more distorted: recall-litigation expense depressed operating profit, while a large UK tax-reserve release lifted net income. The latest quarter also showed slower contact-lens sales, with U.S. channel inventory reductions and weakness in Japan and China. Substantial settlement payments occurred after the July cash-flow reporting date. Cooper extended part—but not all—of its term debt and increased repurchases. Its completed strategic review retained CooperSurgical rather than selling it. The central issue is translating product growth and operating improvements into durable earnings and cash after legal obligations, investment and financing needs.
Sources: 10-K · 2025-10-31 · 10-Q · 2026-07-31 · EX-99.1 · 2026-09-09 · EX-99.2 · 2026-09-09 · 8-K · 2026-02-03
CooperVision supplies daily, two-week and monthly contact lenses through practitioners, optical chains, retailers and distributors. Biofinity is its highest-grossing franchise; MyDay and clariti address different positions in daily silicone-hydrogel lenses. Toric and multifocal products serve more complex prescriptions, while MiSight adds childhood myopia management. Manufacturing efficiency, product availability and successful migration from legacy hydrogels matter alongside demand.
CooperSurgical combines IVF consumables and equipment, genetic testing, donor gametes, cryostorage, contraception and surgical devices. Its economics mix procedure-driven purchases with services recognized over time. Prepaid storage cash is not immediately earned revenue. Neither segment had a customer representing 10% of consolidated revenue in 2023–2025, although customer consolidation can still increase pricing pressure.
Sources: 10-K · 2025-10-31
In the fiscal year ended October 31, 2025, revenue reached $4,092.4 million, but operating income fell to $682.9 million and net income to $374.9 million. CooperVision increased operating income to $729.6 million as sales outpaced expenses. CooperSurgical’s operating income fell to $43.4 million despite higher sales, reflecting inventory and long-lived-asset write-offs, workforce-optimization severance and increased amortization. Consolidated termination-benefit expense was $35.0 million; the annual does not support a complete normalized-profit calculation.
Growth was not uniform or entirely organic. CooperVision benefited from MyDay, Biofinity and MiSight, favorable currency and stronger Americas and EMEA sales, while Asia Pacific was essentially flat and legacy hydrogels declined. CooperSurgical benefited from Paragard and a fuller period of obp Surgical ownership. Segment operating income excludes corporate costs; the $90.1 million corporate deduction remains necessary to reconcile consolidated performance.
Sources: 10-K · 2025-10-31
Fiscal 2025 operating cash flow increased to $796.1 million despite lower profit. Management cited prepaid and other-asset movements and greater noncash write-off add-backs. Cash capital expenditure fell to $362.4 million, leaving an analytical operating-cash-flow-minus-capex residual of $433.7 million before acquisitions, acquisition installments and financing. This is not GAAP profit. Receivables and inventories still absorbed cash, while construction in progress increased.
Repurchase cash spending was $290.1 million in fiscal 2025, and no dividend was paid. At year-end, cash was $110.6 million against $2,505.3 million of debt. Unused revolver availability was additional borrowing capacity, not cash. Subsequent financing changes reduced the maturity concentration but left $550 million due December 17, 2026.
Sources: 10-K · 2025-10-31 · 8-K · 2026-02-03 · 10-Q · 2026-07-31
For the nine months ended July 31, 2026, revenue was $3,171.8 million and operating income fell to $403.8 million, including $272.0 million of net recall-litigation expense. Yet net income rose to $485.7 million, chiefly because of a $307.2 million UK tax-reserve release. That accounting benefit was not operating revenue or evidence of an equivalent cash receipt.
Quarterly CooperVision sales were approximately flat. Management attributed Americas weakness to reduced U.S. channel inventory and Asia Pacific declines to softness in Japan and China. Nine-month operating cash flow of $785.4 million preceded August settlement payments of $306.8 million, including $43.8 million paid directly by insurance. Substantially all claims were settled, not necessarily every remaining exposure. On September 9, the board completed its strategic review and chose to retain CooperSurgical.
Sources: 10-Q · 2026-07-31 · EX-99.2 · 2026-09-09
Material dependencies include limited-source materials, single approved manufacturing sites, regulatory certification, reimbursement, currency and product acceptance. A separate Sauflon-related UK payroll-tax appeal carries a disclosed reasonably possible loss of £0–£71.7 million plus interest, with no liability accrued. The fiscal 2024 ERP-related control weakness was reported remediated at October 31, 2025; management also reported effective disclosure controls at July 31, 2026. These conclusions do not eliminate operational or cybersecurity risk.
Sources: 10-K · 2025-10-31 · 10-Q · 2026-07-31
USD 4.0924 bn
FY2025 · GAAP · consolidated · Attribution: consolidated · Reported currency
| Fiscal year | Value | YoY |
|---|---|---|
| 2025 | USD 4.0924 bn | 5.1% |
| 2024 | USD 3.8954 bn | 8.4% |
| 2023 | USD 3.5932 bn | — |
Consolidated product and service revenue, net of discounts, rebates, returns and other allowances.
Sources: 10-K · 2025-10-31
USD 374.9 m
FY2025 · GAAP · consolidated · Attribution: consolidated · Reported currency
| Fiscal year | Value | YoY |
|---|---|---|
| 2025 | USD 374.9 m | -4.4% |
| 2024 | USD 392.3 m | 33.3% |
| 2023 | USD 294.2 m | — |
Consolidated net income after the income-tax provision.
Sources: 10-K · 2025-10-31
USD 796.1 m
FY2025 · GAAP · consolidated · Attribution: consolidated · Reported currency
| Fiscal year | Value | YoY |
|---|---|---|
| 2025 | USD 796.1 m | 12.2% |
| 2024 | USD 709.3 m | 16.8% |
| 2023 | USD 607.5 m | — |
GAAP operating cash flow after noncash adjustments and operating asset and liability movements.
Sources: 10-K · 2025-10-31
Reading times are estimates for the English text. Financial tables and charts may take additional time.
